Menu
Search
|

Menu

Close
X

Inflarx NV IFRX.OQ (NASDAQ Stock Exchange Global Select Market)

32.40 USD
-1.20 (-3.57%)
As of Jul 20
chart
Previous Close 33.60
Open 33.41
Volume 5,188
3m Avg Volume 14,756
Today’s High 36.00
Today’s Low 32.10
52 Week High 42.79
52 Week Low 14.50
Shares Outstanding (mil) 25.31
Market Capitalization (mil) 850.49
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, EUR)
FY18
0
FY17
0
FY16
0
EPS (EUR)
FY18
-0.408
FY17
-1.003
FY16
-0.520
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
--
8.11
Price to Book (MRQ)
vs sector
5.88
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
--
17.18
LT Debt to Equity (MRQ)
vs sector
--
13.08
Return on Investment (TTM)
vs sector
--
13.18
Return on Equity (TTM)
vs sector
--
15.09

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Winzerlaer Str. 2
JENA     07745

Phone: +493641.508180

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

SPONSORED STORIES